ArticleFrontiers in immunology2026
Exosomal miRNA expression in transplant recipients with EBV-associated post-transplant lymphoproliferative disorder.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epstein-Barr Virus (EBV) drives the development of EBV-associated malignancies such as post-transplant lymphoproliferative disorder (PTLD), evading immune detection. However, how EBV is able to evade immune surveillance is not well understood. One theory suggests that modulation of host microRNAs (miRNAs) expression can help escape immune recognition. EBV-encoded miRNAs support tumor cells survival and manipulate expression of host miRNAs. EBV-infected cells package their content into exosomes, which are transferred throughout the body. Tumor and infected cells by packaging their oncogenic or viral cargo into exosomes can spread the disease and infection. Exosomal cargo is being recognized as potential non-invasive biomarker. Objectives: The aim of this investigation was to analyse the expression of both host- and EBV-encoded miRNAs in exosomes derived from PTLD patients after solid organ transplantation (SOT) or allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: We examined the expression of 28 miRNAs (13 EBV- and 15 host-encoded) from plasma of 23 patients post-HSCT with PTLD (PTLD-HSCT) and 25 post-HSCT patients without PTLD (Non-PTLD-HSCT) at 3 different timepoints (T0 [at the time of HSCT], T1 [3 months post-HSCT] and T2 [6 months post-HSCT]. We also analyzed plasma of 10 solid organ transplant recipients (SOT) with EBV-positive PTLD (PTLD-SOT-EBV(+)) and 8 with EBV-negative PTLD (PTLS-SOT-EBV(-)) and 25 healthy donors. Results: There was no difference in miRNAs expression between PTLD-HSCT and Non-PTLD-HSCT group. Significant differences in miRNAs expression between PTLD patients (post-SOT and post-HSCT) and healthy donors was observed. miRNAs profile differed between EBV(+) and EBV(-) PTLD patients. Conclusions: We highlight the importance of an intermediate control group for selecting PTLD-specific biomarker. Future research should focus on detailed characterization of additional components of the exosomal cargo to identify reliable and non-invasive biomarkers that are critical and specific for PTLD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.